Date published: 2025-9-24

1-800-457-3801

SCBT Portrait Logo
Seach Input

TESSP2 Inhibitors

Chemical inhibitors of TESSP2 can affect its activity through various mechanisms involving the interruption of signal transduction pathways. Wortmannin and LY294002 are potent inhibitors of the PI3K/AKT pathway, a crucial signaling mechanism that TESSP2 may rely on for proper function. By inhibiting PI3K, these chemicals can prevent the activation of AKT, a kinase that phosphorylates a wide array of substrates, potentially including TESSP2 or its partners. This inhibition effectively halts the propagation of signals necessary for TESSP2's functions, resulting in its functional inhibition. Rapamycin, acting downstream, specifically inhibits the mTOR pathway, which is intricately connected to the PI3K/AKT pathway. The inhibition of mTOR by Rapamycin could disrupt TESSP2's involvement in processes regulated by mTOR, such as protein synthesis and cell proliferation, leading to a decrease in TESSP2's functional activity.

Further targeting different aspects of cellular signaling, PD98059 and U0126 function as MEK inhibitors. These inhibitors block the activation of the MEK/ERK pathway, which TESSP2 might utilize. The prevention of ERK activation by these chemicals means that any roles TESSP2 plays in response to ERK-mediated signals would be suppressed. The p38 MAP kinase is another target, with SB203580 impeding its activity. As p38 MAPK is involved in stress responses and cytokine production, the inhibition of this kinase by SB203580 can lead to a reduction in TESSP2's role in these responses. Similarly, SP600125 inhibits the JNK pathway, a signaling route that can modulate TESSP2's function by altering the phosphorylation state of proteins in the pathway. Src family kinases, targeted by the inhibitor PP2, and broad-spectrum kinase activities, including Src family kinases affected by Dasatinib, are essential for multiple phosphorylation events. Inhibition of these kinases can prevent TESSP2 from achieving its active state. Lastly, Imatinib, Erlotinib, and Sorafenib target specific tyrosine kinases such as ABL, EGFR, and RAF, respectively.

SEE ALSO...

Items 131 to 12 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING